Allogeneic Peripheral Blood Stem Cell Transplantation Significantly Increases Risk of Chronic Graft-versus-Host Disease of Lung Compared with Bone Marrow Transplantation  by Alam, Naheed et al.
From the
2Depa
Princ
Ontar
Financial d
Correspon
Allog
ment
Hosp
cine,
ON, C
Received M
 2012 Am
1083-8791
http://dx.dAllogeneic Peripheral Blood Stem Cell
Transplantation Significantly Increases Risk of Chronic
Graft-versus-Host Disease of Lung Compared with
Bone Marrow Transplantation
Naheed Alam,1 Theodore K. Marras,2 Eshetu G. Atenafu,3 Vikas Gupta,1 John Kuruvilla,1
Jeffrey H. Lipton,1 Hans A. Messner,1 Dennis (Dong Hwan) Kim1The risk factors for lung chronic graft-versus-host disease (cGVHD) are not fully elucidated. We attempted
to identify clinical risk factors for lung cGVHD after allogeneic hematopoietic cell transplantation (HCT). A
total of 401 patients who underwent allogeneic HCT between 2000 and 2007 at Princess Margaret Hospital,
Toronto, Canada, were evaluated for lung cGVHD serially starting on day 120 and then annually therafter.
The stem cell source for HCTwas peripheral blood stem cells (PBSCs) in 280 patients (69.8%) and bone mar-
row (BM) in 121 patients (30.2%).With a median follow-up of 36.8 months, 68 patients (17%) had a diagnosis
of lung cGVHD, with a median time of onset of 11.4 months after HCT. Stem cell source was the sole risk
factor identified in univariate analyses. The incidence of lung cGVHD was significantly higher in the patients
receiving PBSCs (14.2% at 1 year and 22.7% at 2 years) compared with those receiving BM (6.8 at 1 year and
14.9% at 2 years; hazard ratio, 1.937; P 5 .02). Multivariate analyses also confirmed the use of PBSCs
as an independent risk factor for lung cGVHD (hazard ratio, 2.408; 95% confidence interval, 1.289-4.496;
P 5 .0058). The use of PBSCs is associated with an increased risk of lung cGVHD compared with the use
of BM for allogeneic HCT.
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Chronic graft-versus-host disease (cGVHD) is one
of the important complications after allogeneic hema-
topoietic cell transplantation (HCT) and a significant
factor in adverse outcomes [1]. The reported preva-
lence of cGVHD ranges from 30% to 70% of all recip-
ients of allogeneic transplants who survive more than 3
months post-HCT [2]. Among them, approximately
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oi.org/10.1016/j.bbmt.2012.07.012presenting with cGVHD eventually develop lung in-
volvement with cGVHD manifesting as bronchiolitis
obliterans (BO) [3].
Lung involvement of cGVHDhasbeen traditionally
considered to increase the severity of cGVHD and to
worsen the quality of life of affected patients [4]. Clinical
risk factors for overall cGVHD have been well
characterized, including the use of peripheral blood
stem cells (PBSCs) as the stem cell source [5], older
recipient age, donor–recipient HLA disparity, and
previous acute GVHD (aGVHD) [3,6]. Previously
reported risk factors for the development of
lung cGVHD included busulfan conditioning,
hypogammaglobulinemia, HLA mismatch, and the use
of unrelated donor cells and methotrexate propylaxis
against GVHD [7]. The use of PBSCs in HCT has in-
creased significantly over the last decade with the in-
creased use of adult unrelated donors; unfortunately,
however, there are relatively little recent data [8]. The
paucity of published data regarding risk factors for
lung cGVHDmight be related to the difficulty in diag-
nosing lung cGVHD. Previously, diagnosis required
pathological confirmation with tissue biopsy in addition
to radiologic studies and pulmonary function tests
(PFTs). However, the National Institutes of Health1905
1906 Biol Blood Marrow Transplant 18:1905-1910, 2012N. Alam et al.(NIH) 2007 consensus criteria for cGVHD allows the
use of imaging with high-resolution chest computed to-
mography (CT) scan and PFTs to diagnose lung
cGVHD in the presence of clinical manifestations [4].
At our center, we have been performing screening
and regular follow-up of PFTs and intensive screening
with CT scans in all patients with suspected lung
cGVHD since 2000. Using our extensive clinical
data, we analyzed clinical risk factors associated with
time to development of lung cGVHD after allogeneic
HCT.MATERIALS AND METHODS
Patients and Transplant Characteristics
Consecutive patients who underwent allogeneic
HCT from either related or unrelated donors between
2000 and 2007 at Princess Margaret Hospital were
included in this study. During that time period, our
policy was to request bone marrow (BM) for unrelated
donors, but we accepted available grafts from any
source. Only patients who were alive at day 100
post-HCT were included in the analysis. This retro-
spective study was approved by the Research Ethical
Board of the University Health Network.
Histocompatibility testing of donors and recipients
was performed at low resolution for HLA-A, -B, and
-C; at high resolution for HLA-DRB1 and -DQB1
DNA-based genotyping for related donor transplanta-
tion; and at high resolution for HLA-A, -B, -C,
-DRB1, and -DQB1 genotyping for unrelated donor
transplantation. The transplant procedures and post-
transplantation management adhered to previously de-
scribed institutional policy [9-12]. Posttransplantation
granulocyte colony-stimulating factor support was not
routinely administered.
GVHD Prophylaxis and Posttransplantation
Management
The majority of GVHD prophylactic regimens in-
cluded cyclosporine used either alone (n 5 25) or in
combination with methotrexate (n 5 269), mycophe-
nolate mofetil (n 5 103), or antithymocyte globulin
(n 5 3). One patient received tacrolimus with myco-
phenolate mofetil. Cyclosporine taper was initiated
at 3 months posttransplantation in patients receiving
cells from an HLA-matched sibling or related donor
and at 6 months posttransplantation in recipients of
HLA-mismatched grafts, unless ongoing therapy for
GVHD necessitated continuation of systemic immu-
nosuppressive treatment.
Pulmonary Surveillance and Monitoring
PFTs were performed in all patients before HCT,
at day 120 posttransplantation, and annually thereaf-ter, as well as whenever clinically indicated. CT scan-
ning was performed not only to diagnose lung
cGVHD, but also to exclude other etiologies of respi-
ratory signs and symptoms, including respiratory tract
infections. Bronchoscopy with bronchoalveolar lavage
(BAL) was also performed to exclude possible infection
when indicated. The medical records, PFT reports,
CT results, and microbiology reports from BAL fluid
analysis were reviewed retrospectively.
Management of Patients with Lung cGVHD
In patients with confirmed lung cGVHD, triple
therapy with a fluticasone/salmetrol inhaler (Advair
metered dose inhaler or diskus, typical dose 500 mg
twice daily; (Glaxose Kline Smith, Mississuga, On-
tario), oral mycophenolate mofetil (1000 mg twice
daily), and either oral clarithromycin (500 mg once
daily) or azithromycin (250 mg once daily) was admin-
istered as an adjunct to short-term oral prednisone
(starting dose 1 mg/kg/day, tapered after clinical stabi-
lization).
Definitions
The day of stem cell infusion was defined as day 0.
aGVHD and cGVHD were diagnosed and graded
using established criteria [4,13]. The severity of
cGVHD was graded at the time of first manifestation
of cGVHD using the NIH consensus criteria [4]. The
diagnosis of lung cGVHD was based on the NIH
consensus criteria as follows. In the absence of nonpul-
monary cGVHD, lung biopsy was required, whereas
in the presence of nonpulmonary cGVHD, lung
involvement could be diagnosed clinically (through
PFTs and radiologic studies). Clinical diagnostic
manifestations of BO included (1) forced expiratory
volume in 1 second (FEV1)/forced vital capacity (FVC)
ratio\0.7 and FEV1 #79% of predicted; (2) evidence
of air trapping, small airway thickening, bronchiectasis
on chest CT or residual volume.120%; and (3) appro-
priate exclusion of infection by BAL fluid analysis [4].
Disease risk for HCT was defined as described
previously [14]. Time to relapse was defined as time
from HCT until disease progression or relapse. Non-
relapse mortality (NRM) was defined as death not re-
lated to disease recurrence or progression. Overall
survival (OS) was defined as the time from HCT until
death from any cause. Time to the development of
lung cGVHD was defined as the interval from
HCT until the onset of lung cGVHD or until the
last follow-up for those patients who did not develop
lung cGVHD.
Statistical Analysis
The study’s primary endpoint was the incidence of
lung cGVHD at 2 years after transplantation. Descrip-
tive statistics were used to assess patient demographics,
Table 1. Patient and Transplant Characteristics
Overall
(n 5 401)
Patients with Lung
cGVHD (n 5 68)
Patients without Lung
cGVHD (n 5 333) P Value
Age, years, median (range) 48 (18-71) 49 (19-68) 47 (18-71) .253
Age <60 years, n (%) 344 (85.8) 59 (86.8) 285 (85.6) .869
Age $60 years, n (%) 57 (14.2) 9 (13.2) 48 (14.4)
Sex, n (%) .053
Male 241 (60.1) 48 (70.6) 193 (58.0)
Female 160 (39.9) 20 (29.4) 140 (42.0)
Diagnosis, n (%) .117
Aplastic anemia 14 (4) 1 (2) 13 (4)
Acute myelogenous leukemia 142 (35) 24 (35) 118 (35)
Acute lymphoblastic leukemia 41 (10) 3 (4) 38 (11)
Myelodysplastic syndrome 33 (8) 4 (6) 29 (9)
Chronic myelogenous leukemia 53 (13) 10 (15) 43 (13)
CLL/SLL 26 (7) 7 (10) 19 (6)
Non-Hodgkin lymphoma 54 (14) 10 (15) 44 (13)
Multiple myeloma 5 (1) 2 (3) 3 (1)
Myelofibrosis 25 (6) 4 (6) 21 (6)
Others 8 (2) 3 (4) 5 (2)
Donor type, n (%) .739
MRD 307 (76.6) 51 (75) 256 (76.9)
MUD/MMD 94 (23.4) 17 (25) 77 (23.1)
Graft source, n (%) .190
BM 121 (30.2) 16 (23.5) 105 (31.5)
PBSCs 280 (69.8) 52 (76.5) 228 (68.5)
Conditioning, n (%) .223
Myeloablative conditioning 282 (70.3) 53 (77.9) 229 (68.8)
Reduced-intensity conditioning 119 (29.7) 15 (22.1) 104 (31.2)
Total body irradiation $12 Gy, n (%) .642
Yes 202 (50.4) 37 (54.4) 165 (49.5)
No 199 (49.6) 31 (45.6) 168 (50.5)
aGVHD grade II-IV, n (%) .306
Yes 284 (70.8) 53 (77.9) 231 (69.4)
No 114 (28.4) 15 (22.1) 99 (29.7)
Missing 3 (0.8) 3 (1)
Cytomegalovirus serostatus, n (%) .910
Recipient2/donor2 118 (29.4) 20 (29.4) 98 (29.4)
Recipient2/donor+ 47 (11.7) 9 (13.2) 38 (11.4)
Recipient+/donor2 67 (16.7) 12 (17.7) 55 (16.5)
Recipient+/donor+ 137 (34.2) 24 (35.3) 113 (33.9)
Missing 32 (8) 3 (4.4) 29 (8.7)
CLL/SLL indicates chronic lymphocytic leukemia/small lymphocytic lymphoma.
Biol Blood Marrow Transplant 18:1905-1910, 2012 1907PBSC as Lung cGVHD Riskdisease characteristics, and related covariates of inter-
est. Categorical variables are expressed as count and
proportions, and continuous variables are expressed
as mean and standard deviation or median and range
as appropriate. The c2 test was used to assess associa-
tions between the onset of chronic GVHD and cate-
gorical variables of interest. The student’s t-test was
used to compare age according to diagnosis of lung
cGVHD. OS was calculated using the Kaplan-Meier
method, and hazard rates (HRs) were obtained by fit-
ting theCox proportional hazardsmodel. The cumula-
tive incidence of lung cGVHD was calculated using
competing-risk analysis [15,16], taking into account
the competing risk of relapse. Finally, a Cox
proportional hazards regression model was used to
determine the overall effect of receiving PBSCs or
BM in the presence of other covariates including
aGVHD, age (dichotomized as \60 years or $60
years), conditioning, use of total body irradiation $12
Gy, and donor type. All P values were 2-sided; results
were considered significant at P\ .05. All statisticalanalyses were performed using SAS version 9.2 (SAS
Institute, Cary, NC) and R version 2.14.0
(R Foundation for Statistical Computing, Vienna,
Austria).RESULTS
Patient Characteristics
A total of 418 patients underwent allogeneic HCT
at our center between 2000 and 2007 and survived be-
yond day 100 posttransplantation. Of these, 401 pa-
tients had data available for evaluation for lung
cGVHD. The baseline characteristics of these patients
are summarized in Table 1. The median duration of
follow-up was 36.8 months (range, 3.0-92.6 months).
The cohort included 307 recipients of a matched re-
lated donor (MRD) transplant and 94 recipients of
a matched unrelated donor (MUD) or mismatched do-
nor (MMD) transplant. The median age of recipients
was 47 years (range, 18-71 years). The 3-year relapse
Figure 1. Cumulative incidence of lung cGVHD in allogeneic HCTre-
cipients. CIF, cumulative incidence function with 95% CI.
1908 Biol Blood Marrow Transplant 18:1905-1910, 2012N. Alam et al.rate was 20.5% 6 2.6%, OS was 64.7% 6 2.6%, and
NRM was 19.5% 6 2.6%.Chronic GVHD
Overall, 267 patients (66%) developed cGVHD.
Among these patients, 117 (44%) presented with mild
cGVHD, 104 (39%) had moderate cGVHD, and 46
(17%) had severe cGVHD. Sixty-eight patients (17%)
developed lung cGVHD, representing 26% of all pa-
tients with cGVHD. Fifty-two of these patients (76%)
had moderate cGVHD and 16 (24%) had severe
cGVHD at the time of diagnosis of lung cGVHD. The
median time to development of lung cGVHD was 349
days (11.4 months; 95% confidence interval [CI], 9.8-
13.0 months; range, 2.3-61.6 months). The incidence
of lung cGVHD was 14.5% at 1 year and 22.6% at 2
years (Figure 1). Fifty-seven patients (84%) with lung
cGVHD developed it within 2 years post-HCT. Only
4 (6%) of the 68 patients with lung cGVHD were diag-
nosed with lung cGVHD beyond 3 years post-HCT.
Other manifestations of cGVHD in the patients with
lung cGVHD included cutaneous (59 of 68; 87%), oral
(51 of 68; 75%), ocular (26 of 68; 38%), gastrointestinal
tract (23 of 68; 34%), and liver (49 of 68; 72%).
In the univariate analysis, various clinical variables
were evaluated as potential risk factors for develop-Table 2. Risk Factors for Time to Development of Lung cGVHD U
Risk Factor Univ
Variable Risk Group P Value
Stem cell source PBSCs .0216
Age Older age ($60 years) .3049
Conditioning Myeloablative .8547
Total body irradiation $12 Gy .6180
Donor type MUD/MMD .4652
aGVHD Grade II-IV .6517ment of lung cGVHD (Table 2). No associations
were noted between lung cGVHD and conditioning
(P 5 .73), recipient age with cutoff of 60 years
(P 5 .37), donor type (P 5 .39), previous episode of
grade II-IV aGVHD (P 5 .50) or grade III-IV
aGVHD (P 5 .14), and CMV reactivation (P 5 .95).
However, the use of PBSCs was significantly asso-
ciated with increasing risk of developing lung
cGVHD. The cumulative incidence of lung cGVHD
was significantly higher in the patients who received
PBSCs (14.2% [95% CI, 9.3%-19%] at 1 year and
22.7% [95% CI, 16.5%-28.9%] at 2 years) than in
those receiving BM (6.8% [95% CI, 1.9%-11.7%] at
1 year and 14.9% [95% CI, 7.6%-22.3%] at 2 years;
P 5 .02; HR, 1.937 [95% CI, 1.108-3.458]).
When accounting for donor type, with MRD com-
pared with MUD/MMD and stem cell source together
as risk factors for time to development of lung cGVHD,
the patients who received PBSCs from anMUD/MMD
were at the greatest risk (15.5% 6 7.5% at 1 year and
40.2% 6 11.7% at 2 years) followed by PBSCs from
an MRD (14.0% 6 2.6% at 1 year and 20.7% 6 3.2%
at 2 years), BM from an MUD/MMD donor
(7.8%6 4.5% at 1 year and 20.0%6 7.3% at 2 years),
and BM from an MRD (6.3% 6 3.1% at 1 year and
11.9%6 4.3% at 2 years) (Figure 3) (Table 3).
Multivariate analysis conducted to confirm the ad-
verse impact of HCT with PBSCs on the risk of devel-
oping lung cGVHD identified PBSC infusion as the
sole independent risk factor for time to development
of lung cGVHD (HR, 2.408; 95% CI, 1.289-4.496;
P 5 .006) (Figure 2).DISCUSSION
Our data reveal several important findings. The
incidence of lung cGVHD based on the NIH consen-
sus criteria was 17%, with a median time of onset of
11.4 months. The use of PBSCs was associated with
an increased risk of lung cGVHD (HR, 2.4), and
most cases of lung cGVHD developed within 3 years
after HCT, with incidence plateauing beyond 3 years.
There are relatively little recent data regarding risk
factors for lung cGVHD. Interestingly, one previous
study investigated similar risk factors and identified
PBSC as a risk factor for BO (HR, 2.5; 95% CI,sing the Fine-Gray Competing-Risk Method
ariate Analysis Multivariate Analysis
HR (95% CI) P Value HR (95% CI)
2.007 (1.107-3.637) .008 2.384 (1.254-4.531)
1.431 (0.722-2.838)
0.947 (0.530-1.693)
0.883 (0.543-1.438)
1.139 (0.705-2.147) .079 1.706 (0.939-3.097)
1.139 (0.648-2.001)
Figure 2. Cumulative incidence of lung cGVHD according to stem cell
source. In multivariate Cox proportional hazard analysis, use of PBSCs
was the sole independent risk factor for lung cGVHD (HR, 2.408;
95% CI, 1.289-4.496; P 5 .006).
Table 3. Comparison of Donor Type and StemCell Source as
a Risk Factor for Lung cGVHD
Risk Factor for Lung
cGVHD P Value HR (95% CI)
P Value among
4 Groups
MRD, BMT — 1.000 .022
MRD, PBSCT .032 1.262 (1.026-2.204)
MUD/MMD, BMT .348 1.504 (0.772-2.063) -
MUD/MMD, PBSCT .004 1.970 (1.203-3.228) -
Biol Blood Marrow Transplant 18:1905-1910, 2012 1909PBSC as Lung cGVHD Risk1.2-5.5) [17]. In the present study, the overall inci-
dence was 17%, somewhat higher than that in most
previous reports. However, the use of PBSCs and
MUDs/MMDs have increased over the last decade at
our center, which might have affected overall inci-
dence as well as the incidence of lung cGVHD. At
our center, we have been conducting routine pulmo-
nary surveillance at day 120 after allogeneic HCT
and regular annual monitoring of PFT results since
2000 [18]. Accordingly, our current data were col-
lected in a prospective manner. This aggressive screen-
ing policy at our center may provide a plausible
explanation for our higher incidence of lung cGVHD
than reported in other centers. In addition, our study
population includes only patients who survived beyond
day 100 after allogeneic HCT.
In the present study, the median time to develop-
ment of lung cGVHD was close to 1 year (range, 2.5
months to 3 years), underscoring the need for close
monitoring of these patients, starting as early as 3Figure 3. Cumulative incidence of lung cGVHD according to donor type and smonths post-HCT to enable early diagnosis and
prompt treatment. In addition, pulmonary surveillance
should be continued for at least 3 years post-HCT. Ac-
cordingly, regular pulmonary surveillance with PFTs
is strongly recommended in all allogeneic HCT recip-
ients, starting at 3-6 months after transplantation and
extending for at least 3 years.
The development of lung cGVHD seemed to pla-
teau after 3 years in our study population. After 3 years,
only 4 patients (1%) were diagnosed with lung
cGVHD. This finding suggests a relatively low risk
of lung cGVHD in the patientwho developed a pulmo-
nary abnormality beyond 3 years after HCT.
In this study, PBSC as the stem cell source was the
sole risk factor significantly associated with the devel-
opment of lung cGVHD. The use of PBSCs has been
associated with a greater risk of overall cGVHD [5]. In
a previous study, cGVHD after HCT using PBSCs
was associated with more successive treatments and
longer duration of steroid therapy compared with
cGVHD after HCT using BM [19]. These differences
might be related to the fact that PBSCs have more
T cells compared with BM and are also qualitatively
different from BM [20-22]. Importantly, although
our cohort did contain more related donors than
unrelated donors, this might or might not have
influenced the results. Furthur studies are warranted
to explore this question in detail [23-25].tem cell source. BMT, BM transplantation; PBSCT, PBSC transplantation.
1910 Biol Blood Marrow Transplant 18:1905-1910, 2012N. Alam et al.Up to 50% of patients with moderate cGVHD and
up to 60% of those with severe cGVHDmay have lung
involvement [26]. In our study, 50% of patients with
moderate lung cGVHD and 35% of those with severe
lung cGVHD had lung involvement, highlighting the
fact that this subset of patients is at high risk and needs
more vigorous PFT monitoring.
Inconclusion, thepresent study is thefirst to examine
risk factors for lung cGVHD using NIH criteria. Based
on our observations, we recommend early screening of
these patients at 4 months after allogeneic HCT and
then annual close monitoring for at least up to 3 years.ACKNOWLEDGMENTS
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